2025 India Biologics Safety Testing Market Revenue Opportunities Report
Description
The 2025 India Biologics Safety Testing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biologics Safety Testing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biologics safety testing market in India include Charles River Laboratories International Inc., Eurofins Scientific SE, Merck KGaA (MilliporeSigma), and Samsung Biologics. Charles River Laboratories is known for its extensive expertise in preclinical and clinical research support, offering rigorous safety testing procedures that support regulatory compliance. Eurofins Scientific has invested heavily in India, notably setting up an advanced laboratory campus in Genome Valley, Hyderabad, to serve both global pharmaceutical and local biotech clients with cutting-edge testing services. Merck KGaA emphasizes innovative technologies, such as their validated genetic stability testing, enhancing biosafety testing workflows. Samsung Biologics leverages state-of-the-art biomanufacturing capabilities to meet growing market demand, supporting pharmaceutical safety and quality assurance efforts.
Additionally, Indian biosimilars leader Biocon Biologics plays a significant role domestically, being one of the top 15 global biomanufacturing companies by capacity. Biocon specializes in developing and commercializing high-quality biosimilars ranging from insulins to monoclonal antibodies, underpinned by strong compliance with international cGMP standards. Alongside these global and local firms, the Indian biological safety testing market is growing rapidly, driven by the robust pharmaceutical and vaccine production sectors, government initiatives, and a rising demand for safety testing products and services. The market is expected to reach revenues of over USD 419 million by 2033, supported largely by testing reagents, kits, and services, underscoring the strategic role of these key companies in India’s expanding biologics safety testing landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biologics Safety Testing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biologics safety testing market in India include Charles River Laboratories International Inc., Eurofins Scientific SE, Merck KGaA (MilliporeSigma), and Samsung Biologics. Charles River Laboratories is known for its extensive expertise in preclinical and clinical research support, offering rigorous safety testing procedures that support regulatory compliance. Eurofins Scientific has invested heavily in India, notably setting up an advanced laboratory campus in Genome Valley, Hyderabad, to serve both global pharmaceutical and local biotech clients with cutting-edge testing services. Merck KGaA emphasizes innovative technologies, such as their validated genetic stability testing, enhancing biosafety testing workflows. Samsung Biologics leverages state-of-the-art biomanufacturing capabilities to meet growing market demand, supporting pharmaceutical safety and quality assurance efforts.
Additionally, Indian biosimilars leader Biocon Biologics plays a significant role domestically, being one of the top 15 global biomanufacturing companies by capacity. Biocon specializes in developing and commercializing high-quality biosimilars ranging from insulins to monoclonal antibodies, underpinned by strong compliance with international cGMP standards. Alongside these global and local firms, the Indian biological safety testing market is growing rapidly, driven by the robust pharmaceutical and vaccine production sectors, government initiatives, and a rising demand for safety testing products and services. The market is expected to reach revenues of over USD 419 million by 2033, supported largely by testing reagents, kits, and services, underscoring the strategic role of these key companies in India’s expanding biologics safety testing landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
